Amplicare announced the addition of two new benefits to its suite of solutions aimed at helping pharmacists improve patient care and health outcomes.
Amplicare's platform now includes a capability that identifies pharmacy patients at a high risk of experiencing an opioid overdose in their household. Each opportunity is accompanied by tools to help pharmacists educate patients about Naloxone and its availability over-the-counter without a prescription.
Amplicare concurrently rolled out a similar capability to help pharmacists increase the rate of vaccinations, which is timely in the current flu season. These updates provide pharmacists the opportunity to act on health interventions within their workflows, easily monitor progress, and manage the life cycle of these interventions.
"Community pharmacies are uniquely positioned in our healthcare system as the most accessible healthcare providers for patients, and they stand at the front lines of the fight against health crises," said Matt Johnson, Pharm.D., CEO of Amplicare. "As the role of pharmacists moves beyond dispensing prescriptions, our focus is to help them tap into the growing number of opportunities that exist in the clinical and business side of healthcare. These new benefits make it easier for them to mobilize vaccinations across their patient base and significantly reduce the life-threatening effects of opioid overdoses."
The introduction of these two new capabilities is in line with Amplicare's long-term goal of using technology to empower healthcare providers to better serve patients. Last year, the company rebranded from iMedicare to Amplicare as it expanded its solutions beyond Medicare plan comparisons to include tools to streamline workflows and identify opportunities for pharmacists to provide higher levels of care to patients.